Keyword Index

A

  • Antibiotic resistance CORRELATION BETWEEN BIOFILM OF DENTAL MICROBES AND ANTIBIOTIC RESISTANCE, IN VITRO STUDY [Volume 68, Issue 2, 2023, Pages 188-205]
  • Anti-cancer agents PYRIDINE DERIVATIVES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS [Volume 68, Issue 2, 2023, Pages 64-81]
  • Anti-cancer agents VEGFER-2 INHIBITORS AND QUINAZOLINE-BASED ANTICANCER AGENTS [Volume 68, Issue 2, 2023, Pages 111-129]
  • Atropine Sulfate (AS) PREPARATION AND CHARACTERIZATION OF ATROPINE SULFATE ORODISPERSIBLE TABLETS [Volume 68, Issue 2, 2023, Pages 43-63]
  • Aurora EXPLORING THE PROTEIN KINASE INHIBITORY ACTIVITY OF QUINAZOLINES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS [Volume 68, Issue 2, 2023, Pages 82-110]

B

  • BCR-ABL AN OVERVIEW OF QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS [Volume 68, Issue 2, 2023, Pages 130-158]
  • Biofilm CORRELATION BETWEEN BIOFILM OF DENTAL MICROBES AND ANTIBIOTIC RESISTANCE, IN VITRO STUDY [Volume 68, Issue 2, 2023, Pages 188-205]
  • Biological targets PYRIDINE DERIVATIVES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS [Volume 68, Issue 2, 2023, Pages 64-81]

C

  • Cancer FORMULATION AND CHARACTERIZATION OF THERMOSENSITIVE CHITOSAN HYDROGEL LOADED WITH ERLOTINIB: FULL FACTORIAL DESIGN OF RELEASE DATA [Volume 68, Issue 2, 2023, Pages 1-27]
  • Chitosan FORMULATION AND CHARACTERIZATION OF THERMOSENSITIVE CHITOSAN HYDROGEL LOADED WITH ERLOTINIB: FULL FACTORIAL DESIGN OF RELEASE DATA [Volume 68, Issue 2, 2023, Pages 1-27]

D

  • Dental bacteria CORRELATION BETWEEN BIOFILM OF DENTAL MICROBES AND ANTIBIOTIC RESISTANCE, IN VITRO STUDY [Volume 68, Issue 2, 2023, Pages 188-205]

E

  • Erlotinib FORMULATION AND CHARACTERIZATION OF THERMOSENSITIVE CHITOSAN HYDROGEL LOADED WITH ERLOTINIB: FULL FACTORIAL DESIGN OF RELEASE DATA [Volume 68, Issue 2, 2023, Pages 1-27]

H

  • Hsp90 AN OVERVIEW OF QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS [Volume 68, Issue 2, 2023, Pages 130-158]

I

  • ICH DEVELOPMENT AND VALIDATION OF LC-MS METHOD FOR SIMULTANEOUS DETERMINATION OF PYRIMETHAMINE AND SULFADOXINE IN THE PHARMACEUTICAL PREPARATION [Volume 68, Issue 2, 2023, Pages 159-171]
  • In vitro release FORMULATION AND CHARACTERIZATION OF THERMOSENSITIVE CHITOSAN HYDROGEL LOADED WITH ERLOTINIB: FULL FACTORIAL DESIGN OF RELEASE DATA [Volume 68, Issue 2, 2023, Pages 1-27]

L

  • LC-MS method DEVELOPMENT AND VALIDATION OF LC-MS METHOD FOR SIMULTANEOUS DETERMINATION OF PYRIMETHAMINE AND SULFADOXINE IN THE PHARMACEUTICAL PREPARATION [Volume 68, Issue 2, 2023, Pages 159-171]

N

  • Nanoparticles FORMULATION AND CHARACTERIZATION OF THERMOSENSITIVE CHITOSAN HYDROGEL LOADED WITH ERLOTINIB: FULL FACTORIAL DESIGN OF RELEASE DATA [Volume 68, Issue 2, 2023, Pages 1-27]

O

  • Organophosphate (op) PREPARATION AND CHARACTERIZATION OF ATROPINE SULFATE ORODISPERSIBLE TABLETS [Volume 68, Issue 2, 2023, Pages 43-63]
  • Orodispersible tablets (ODT) PREPARATION AND CHARACTERIZATION OF ATROPINE SULFATE ORODISPERSIBLE TABLETS [Volume 68, Issue 2, 2023, Pages 43-63]

P

  • Premature Ejaculation FORMULATION AND CHARACTERIZATION OF DIFFERENT TOPICAL HYDROGELS LOADED WITH SILDENAFIL CITRATE [Volume 68, Issue 2, 2023, Pages 28-42]
  • Pyridine derivative PYRIDINE DERIVATIVES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS [Volume 68, Issue 2, 2023, Pages 64-81]
  • Pyrimethamine DEVELOPMENT AND VALIDATION OF LC-MS METHOD FOR SIMULTANEOUS DETERMINATION OF PYRIMETHAMINE AND SULFADOXINE IN THE PHARMACEUTICAL PREPARATION [Volume 68, Issue 2, 2023, Pages 159-171]

Q

  • Quinazoline EXPLORING THE PROTEIN KINASE INHIBITORY ACTIVITY OF QUINAZOLINES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS [Volume 68, Issue 2, 2023, Pages 82-110]
  • Quinazoline VEGFER-2 INHIBITORS AND QUINAZOLINE-BASED ANTICANCER AGENTS [Volume 68, Issue 2, 2023, Pages 111-129]
  • Quinoline AN OVERVIEW OF QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS [Volume 68, Issue 2, 2023, Pages 130-158]

R

  • Rabies Virus MONITORING OF RABIES IMMUNE STATUS IN EXPERIMENTALLY VACCINATED PUPPIES [Volume 68, Issue 2, 2023, Pages 172-187]

S

  • Serine/threonine kinases EXPLORING THE PROTEIN KINASE INHIBITORY ACTIVITY OF QUINAZOLINES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS [Volume 68, Issue 2, 2023, Pages 82-110]
  • Sulfadoxine DEVELOPMENT AND VALIDATION OF LC-MS METHOD FOR SIMULTANEOUS DETERMINATION OF PYRIMETHAMINE AND SULFADOXINE IN THE PHARMACEUTICAL PREPARATION [Volume 68, Issue 2, 2023, Pages 159-171]

T

  • Topoisomerases AN OVERVIEW OF QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS [Volume 68, Issue 2, 2023, Pages 130-158]
  • Tubulin inhibitors AN OVERVIEW OF QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS [Volume 68, Issue 2, 2023, Pages 130-158]
  • Tyrosine kinases EXPLORING THE PROTEIN KINASE INHIBITORY ACTIVITY OF QUINAZOLINES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS [Volume 68, Issue 2, 2023, Pages 82-110]

V

  • Vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors VEGFER-2 INHIBITORS AND QUINAZOLINE-BASED ANTICANCER AGENTS [Volume 68, Issue 2, 2023, Pages 111-129]
  • VEGFR EXPLORING THE PROTEIN KINASE INHIBITORY ACTIVITY OF QUINAZOLINES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS [Volume 68, Issue 2, 2023, Pages 82-110]
  • VEGFR AN OVERVIEW OF QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS [Volume 68, Issue 2, 2023, Pages 130-158]